Telomir-1 Reduces Tumor Growth and Spread in Aggressive Triple-Negative Breast Cancer Models
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals Inc. has reported promising preclinical results for its compound Telomir-1 in aggressive triple-negative breast cancer models. The study, conducted with BioReperia, demonstrated that Telomir-1 significantly reduced tumor growth and cancer spread in zebrafish models. It was effective as a standalone treatment and in combination with paclitaxel, especially in chemotherapy-resistant models. These findings will guide future clinical trials and patient selection as the company advances its IND-enabling activities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments